ORMP Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Oramed Pharmaceuticals's net margin of -49.65%. Oramed Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.13%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than Oramed Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Oramed Pharmaceuticals's net income of -$19.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.55x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.30x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Oramed Pharmaceuticals's net margin of --. Oramed Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.13%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 19745.64%. Given that Oragenics has higher upside potential than Oramed Pharmaceuticals, analysts believe Oragenics is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Oramed Pharmaceuticals's net income of -$19.6M is lower than Oragenics's net income of -$2.5M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.55x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.30x versus 1.78x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Oramed Pharmaceuticals's net margin of -2357.27%. Oramed Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.13%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Oramed Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Oramed Pharmaceuticals's net income of -$19.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.55x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.30x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Oramed Pharmaceuticals's net margin of --. Oramed Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.13%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6056.46%. Given that Theriva Biologics has higher upside potential than Oramed Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Oramed Pharmaceuticals's net income of -$19.6M is lower than Theriva Biologics's net income of -$7.7M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.55x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.30x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.